Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry Expected To Reach By 2029, Starting From 2025 Levels?
The market for asthma and chronic obstructive pulmonary disease (COPD) drugs has demonstrated robust expansion over recent years. This market is anticipated to expand from $32.52 billion in 2024 to reach $35.66 billion by 2025, reflecting a compound annual growth rate (CAGR) of 9.6%. The expansion observed in prior periods can be attributed to several factors, including rising air pollution levels, increased rates of tobacco smoking, heightened public awareness of respiratory illnesses, the broader adoption of corticosteroids and bronchodilators, and an increase in healthcare expenditure.
The market for asthma and chronic obstructive pulmonary disease (copd) drugs is anticipated to experience substantial expansion over the coming years. This market is projected to reach $50.99 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.4%. This expansion throughout the forecast period can be attributed to factors such as the rising demand for personalized medicine, the increasing integration of biologics and cutting-edge therapies, a higher occurrence of environmental allergies, a surge in clinical trials and subsequent approvals, and the escalating prevalence of non-communicable diseases. Key trends anticipated during this period encompass smart inhalers enhanced by technology, the development of bronchodilators with dual actions, the merging of electronic health records (EHR) with drug-related data, breakthroughs in biopharmaceutical molecules, and the incorporation of machine learning into the process of drug discovery.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp
Which Factors And Drivers Are Influencing The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2025?
The expanding occurrence of smoking is anticipated to fuel the expansion of the asthma and COPD drugs market in the future. Smoking refers to the practice of consuming tobacco products by inhaling the smoke, which can lead to serious health issues such as lung cancer and heart disease. The rising prevalence of smoking is primarily driven by social influence, where peer pressure, cultural norms, and social environments encourage individuals to start and continue smoking. Medications for asthma and chronic obstructive pulmonary disease (COPD) assist in mitigating the respiratory damage caused by smoking by reducing inflammation, relaxing airway muscles, and improving airflow, thereby alleviating symptoms and enhancing lung function. For instance, in 2024, according to the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, a study on smoking trends among young people showed a notable increase in smoking rates, rising from 22.5% of respondents in 2022 to 40.1% in 2024. Therefore, the growing frequency of smoking is driving the growth of the asthma and COPD drugs market.
What Are The Leading Segments Analyzed In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?
The asthma and chronic obstructive pulmonary disease (COPD) drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers
2) By Route Of Administration: Inhalation, Oral, Injection, Nasal, Other Route Of Administrations
3) By Patient Group: Adult, Pediatric, Geriatric
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Subsegments
1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines
2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids
3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors
What Long-Term Trends Will Shape The Future Growth Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?
Leading companies in the asthma and COPD drugs market are prioritizing the creation of innovative formulations, such as fixed-dose combination (FDC) drugs, to enhance treatment adherence and therapeutic effectiveness. A fixed-dose combination (FDC) drug is a singular dosage form that incorporates two or more active ingredients, aiding in the management of asthma and COPD by merging bronchodilators and anti-inflammatories to improve symptom regulation and patient compliance. For example, in June 2022, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched Indamet, a novel fixed-dose combination (FDC) drug comprising Indacaterol, a long-acting beta-agonist (LABA), and Mometasone Furoate, an inhaled corticosteroid (ICS), intended for the treatment of uncontrolled asthma. Indamet represents the first FDC of its kind to be approved by the Drug Controller General of India (DCGI) and introduced in the nation, available in three strengths: Indacaterol 150 mcg combined with Mometasone 80 mcg, 160 mcg, or 320 mcg, administered once daily. This specific formulation is designed to optimize lung function, enhance symptom control, reduce the frequency of exacerbations, and improve treatment adherence among adult and adolescent patients aged 12 years and above.
Which Major Firms Are Strengthening Their Position In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?
Major companies operating in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, Aurobindo Pharma
Download The Full Report For Exclusive Market Findings:
Which Region Shows The Highest Potential For Future Expansion In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market?
North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (COPD) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp
Browse Through More Reports Similar to the Global Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2025, By The Business Research Company
Anti Asthmatics And Copd Drugs Global Market Report 2025
Digital Dose Inhalers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/digital-dose-inhalers-global-market-report
Inhaled Antibiotics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/inhaled-antibiotics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model